(Total Views: 641)
Posted On: 05/20/2022 6:29:20 PM
Post# of 154140
Re: Good to go #123492
there is zero chance Leronlimab has not been continued in the surviving patients in this trial. i am using common sense in this statement only.
mTNBC is a huge indication, and just a part of all potential CCR5 dependent tumors. We would have had BTD had we been better than SOC, instead we equaled it. Today, we will crush SOC. You know what, even if LL was not continued, (which will be shown, NOT to be the case), but even if it were not, we will still crush SOC. Even if we extend SOC to 15 months, that might be sufficient to warrant BTD.
Take it that it was continued as per schedule, LL overall survivability becomes 18 months and counting. Could it be 1 and 1/2 years? Yeah, and counting.
Leronlimab stops circulating tumor cells. No metastasis. Tumors shrink and necrose. They die. The trial was not stopped. Kelly would have made the worst decision of his career if this trial was stopped.
mTNBC is a huge indication, and just a part of all potential CCR5 dependent tumors. We would have had BTD had we been better than SOC, instead we equaled it. Today, we will crush SOC. You know what, even if LL was not continued, (which will be shown, NOT to be the case), but even if it were not, we will still crush SOC. Even if we extend SOC to 15 months, that might be sufficient to warrant BTD.
Take it that it was continued as per schedule, LL overall survivability becomes 18 months and counting. Could it be 1 and 1/2 years? Yeah, and counting.
Leronlimab stops circulating tumor cells. No metastasis. Tumors shrink and necrose. They die. The trial was not stopped. Kelly would have made the worst decision of his career if this trial was stopped.
(4)
(0)
